Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

about

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

Item

http://www.wikidata.org/entity/Q35996015

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

@ast

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

@en

type

Item

label

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

@ast

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

@en

prefLabel

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

@ast

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

@en

P1476

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.

@en

P2093

Paul P Dobesh

http://www.w3.org/2001/XMLSchema#string

P2860

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

Managing oral anticoagulant therapy.

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.

Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

Clinical epidemiology of acute myocardial infarction.

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

P304

169S-178S

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.24.15.169S.43160

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

10 Pt 2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15624336

http://www.w3.org/2001/XMLSchema#string